When the active substance is specified for compressed tablet manufacture, the process-limiting variable is rarely the inherent chemical stability of the dried API; rather, the blend’s response to high-speed rotary pressing controls whether the finished tablets can meet mass, content, and dissolution specifications without reject-level incidence of capping or lamination. Tablets for companion animal and production animal use are manufactured under 21 CFR 210 and 21 CFR 211 current good manufacturing practice, with release testing aligned to Ph. Eur. 2.9.5 for uniformity of mass, USP <905> for content uniformity, Ph. Eur. 2.9.3 or USP <711> for dissolution, and Ph. Eur. 2.9.1 for disintegration. The API is incorporated at 1–45 % w/w in a direct-compression or wet-granulated core; unit strengths commonly range from 5 mg to 800 mg active per 150–1500 mg core. The downstream process begins with geometric pre-blending of the active with lactose monohydrate or microcrystalline cellulose at 10–60 % w/w, followed by addition of croscarmellose sodium 1–4 % w/w as disintegrant, granulation with povidone binder solution at 1–5 % w/w solids in a high-shear mixer, and drying in a fluid-bed dryer with inlet air temperature 55–70 °C to final moisture ≤ 2.5 %. The dried granulate is sieved through 0.8–1.5 mm screen, lubricated with magnesium stearate 0.5–1.5 % w/w, and compressed on a rotary tablet press with compression force 8–25 kN; tablet hardness is maintained at 60–120 N and friability below 0.8 % after 100 rotations. For low-dose actives below 10 mg per tablet, direct compression may substitute for wet granulation only if the API is milled to D90 ≤ 20 µm and the final blend is discharged under controlled humidity RH ≤ 40 % to prevent agglomeration. The finished dosage forms coming off the press include single-scored tablets, flavoured chewable tablets, and dual-layer tablets with immediate and modified-release segments for companion animals.

What Sterility and Endotoxin Thresholds Govern Multi-Dose Injectable Veterinary Preparations?

Parenteral veterinary preparations operate within the narrowest processing window of all finished dosage forms, because sterility assurance, endotoxin burden, particulate load, and chemical stability must be proven simultaneously on each batch. Injectable manufacturing is governed by 21 CFR 210/211 and EU GMP Annex 1 cleanroom classification, with release testing against Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxins, and Ph. Eur. 2.6.2 or USP <790> for visible and subvisible particles. The active is formulated at 1–30 % w/v; isotonicity is adjusted with sodium chloride or mannitol to 250–350 mOsm/kg, and pH is fixed within 3.5–7.5 according to solubility data and forced-degradation studies. For aqueous solutions, the bulk is compounded in stainless-steel vessels under nitrogen overlay, passed through a 0.8 µm prefilter, then through a <0.22 µm sterilising-grade membrane into sterile receiving vessels. Filling is performed in ISO 14644-1 Class A laminar-airflow zones with continuous non-viable particle monitoring; line speed is deliberately constrained by fill-volume tolerance and vial neck diameter rather than by pump capacity.

Thermolabile actives that cannot withstand terminal autoclaving at 121 °C for 15 min are processed by aseptic filtration and lyophilisation. The filtered solution is filled into siliconised type I glass vials, partially stoppered, and loaded onto freeze-dryer shelves; the cycle typically starts from −40 °C shelf temperature and ramps to +25 °C over 48–72 h, followed by nitrogen backfill and residual moisture acceptance at ≤ 1.0 %. Injectable suspensions require active particle size reduction to D90 ≤ 20 µm and high-shear dispersion under aseptic conditions; viscosity is maintained below 500 cP at 20 °C to remain syringeable through 18–21 gauge needles. Finished presentations applicable to this route include aqueous injection solutions, injectable suspensions, and lyophilised powders for reconstitution with water for injection. Operational limitations include incompatibility of the API with chlorinated diluents in certain multi-dose presentations and the requirement to avoid amine-containing buffers when the active contains electrophilic functional groups prone to nucleophilic degradation.

Capsule filling of veterinary actives becomes technically demanding when the active substance is electrostatic or poorly free-flowing, because dosator and tamping-pin machines meter the dose volumetrically rather than gravimetrically. The API is diluted to 5–75 % w/w with lactose, mannitol, or microcrystalline cellulose, and croscarmellose sodium is included at 1–3 % w/w as disintegrant; colloidal silicon dioxide 0.1–0.5 % w/w controls hopper flow. The process must comply with 21 CFR 210/211 for finished veterinary drug products, while hard gelatin or HPMC shells meet Ph. Eur. 3.1.1 or Ph. Eur. 3.1.34. Fill weight is set at 50–900 mg product per capsule, and automatic capsule fillers operate at 10,000–150,000 capsules/h; blend uniformity is verified by stratified sampling at the start, middle, and end of each hopper, with acceptance at %RSD ≤ 4.0 % for active loads above 25 mg per capsule and %RSD ≤ 5.0 % for lower strengths. When gelatin shells are used, the filling suite is held at RH ≤ 45 %, and magnesium stearate lubrication must not exceed 5 min at 1 % w/w to avoid reduced shell disintegration. Final capsule presentations include flavoured oral capsules for dogs and cats, enteric-coated capsules for acid-labile actives, and sprinkle-type capsules that are opened and mixed with companion animal food.

When Low-Dose Water Medication Requires Dust-Controlled Oral Powders

Oral powders for water medication impose distinct constraints from tablets: the dose is administered over many hours through drinking water, so the active must remain dispersed or dissolved at field concentrations without generating dust that risks operator exposure during mixing. The active is diluted to 1–20 % w/w in a carrier consisting of lactose monohydrate, dextrose, or a citric acid–sodium bicarbonate effervescent pair; the final medicated drinking water concentration is typically 100–1000 mg/L active, with the individual dose determined by water consumption and body weight. Manufacturing uses low-shear tumble blending for 15–25 min, sifting through 150–500 µm mesh, and filling into foil-laminate sachets or bulk containers at RH ≤ 40 %. Compliance requires adherence to 21 CFR 210/211 for finished veterinary drug products and, where the powder is incorporated into feed, Regulation (EU) 2019/4 requirements for medicated feeding stuffs. Terminal product types include water-soluble powder sachets for poultry and swine, oral dusting powders for sheep, and large-volume bulk powders for on-farm dosing pumps.

In granulated oral forms, dust retention and flowability are improved by converting the API blend into dense, sieve-defined agglomerates, but the endpoint of wet granulation must be fixed by torque or power-consumption measurement because over-granulation produces slow-dissolving dense granules and under-granulation produces fines that segregate during filling. The active is loaded at 10–60 % w/w; the dry blend is granulated in a high-shear processor with impeller speed 100–300 rpm and chopper speed 1000–3000 rpm, adding purified water or aqueous binder solution at 2–10 % w/w. Drying in a fluid-bed dryer at inlet temperature 60–75 °C proceeds to final moisture ≤ 2.0 %, followed by oscillating sieving through 0.5–2.0 mm screens to obtain granules ready for further tableting or direct dispensing. Granule flow is evaluated using Ph. Eur. 2.9.36, and particle-size distribution is controlled by sieve analysis according to Ph. Eur. 2.9.38; the process complies with 21 CFR 211 and stability expectations of VICH GL3. The precise impeller torque endpoint is product-specific, and published data for this active-excipient configuration is limited; pilot-scale mixer studies with torque measurement are therefore mandatory before scale-up. Resulting granule formats include granular feed top-dress, granules for reconstitution before oral drenching, and granulated intermediates for subsequent premix dilution.

Post-Pelleting Recovery of Medicated Premixes Depends on Carrier Oil Loading and Ribbon Blender Configuration

Medicated premix operations for swine, poultry, and cattle feed require a carrier that retains the active through feed-mill handling, prevents segregation in bulk transport, and does not generate active-rich fines during pelleting. The API is incorporated at 2–10 % w/w into a carrier matrix of calcium carbonate, wheat middlings, or lactose; the concentrated premix is then diluted into complete feed to reach final active concentrations of 50–500 mg/kg. Production uses a horizontal ribbon blender with trough clearance of 2–5 mm and fill ratio 60–80 % of gross volume; the active is added by geometric dilution in 3–5 steps, and mixing continues for 10–20 min after final addition. Batch uniformity is verified by sampling according to ISO 6497:2002, with acceptance at CV ≤ 5.0 % for active distribution.

After blending, the premix is metered through loss-in-weight feeders into complete feed mixers, then conditioned with steam at 70–85 °C and pelleted through 2.5–4.0 mm dies. Post-pelleting active recovery must be monitored because thermal degradation may occur if the active substance has a melting point below 90 °C or if the steam residence time exceeds 60 s; in practice, a recovery threshold of ≥ 90 % of theoretical active content after pelleting is a common release criterion. Compliance is anchored to Regulation (EU) 2019/4 for medicated feed, EU GMP Annex 4 for veterinary medicinal products, and 21 CFR 225 for medicated feed manufacturing in the United States. Finished feed presentations include concentrated non-pelleted premises for on-farm mixing, pelleted medicated feeds for swine and poultry, and mineral-block premix intermediates for ruminants.

Viscosity Boundaries and Co-Solvent Selection for Oral Drench Syringeability

For oral solutions and drenches, the co-solvent system must maintain the active in complete solution over the claimed shelf life without creating a viscous product that cannot be delivered through automatic drenching equipment. The API is dissolved at 2–30 % w/v in a matrix of purified water, propylene glycol, glycerol, or ethanol, with preservative sodium benzoate at 0.1–0.5 % w/v and buffer salts to hold pH between 3.5 and 6.0. Compounding proceeds in stainless-steel vessels with high-torque propeller agitation, followed by clarification filtration at <0.45 µm and filling into amber PET or type III glass bottles at 10–500 mL volumes using piston or peristaltic fillers. Viscosity is measured at 20 °C; when rotational viscometer values exceed 100 cP, automatic drench guns may deliver incomplete volumes, so glycerol content is reduced or the solution is warmed during filling. Release testing includes Ph. Eur. 2.2.10 for clarity and opalescence, Ph. Eur. 2.2.8 for pH, and 21 CFR 210/211 for finished product GMP. Filling lines produce oral drenches for cattle and sheep, concentrated drinking-water solutions for poultry, and pump-spray oral solutions for swine nurseries.